FORMULATIONS

SR.NO PRODUCT NAME STRENGTH DOSAGE
1 ANTI-CANCER
Bendamustine Hydrochloride Monohydrate ^ # 100 mg/ml Injectable
Carmustine * 100 mg/vial Injectable
Cyclophosphamide Monohydrate *#(sterile powder) 0.5 gm/vial, 1 gm/vial, 2gm/vial Injectable
Melphalan Hydrochloride *# 50 mg/vial Injectable

2

RARE DRUGS
Carglumic Acid * 200 mg Tablet
Fomepizole * 1 gm/ml Injectable
Fomepizole Sulfate * 5 mg/ml Injectable
Trientine Hydrochloride USP* 250mg Capsule
3 PHOSPHATE BINDERS
Sevelamer Carbonate 400 & 800 mg Tablet
Sevelamer Hydrochloride* 400 & 800 mg Tablet
4 HAEMATOLOGICALS
Argatroban USP ^ # 250 mg/2.5 ml Injectable
Iron Sucrose Complex USP * # 2.5 ml & 5 ml Injectable
Phytonadione (Vitamin K1) * 5 mg Tablet
Phytonadione (Vitamin K1) *# (Emulsion) 10 mg/ml Injectable
5 CARDIOVASCULAR
Colesevelam Hydrochloride * # 625 mg Tablet
Hydralazine Hydrochloride USP # 20 mg/ml Injectable
Nicardipine Hydrochloride USP ^ # 2.5 mg/ml Injectable
6 ANTI-RHEUMATIC
Penicillamine ^ 250 mg Capsule
7 CNS
Fosaprepitant Dimeglumine * 150 mg/vial Injectable
Benztropine Mesylate USP ^# 2mg/ml Injectable
8 ANESTHETICS
Ropivacaine Hydrochloride # 10 mg/ml (1.0%), 5 mg/ml (0.5%) Injectable
9 SMOKING DETTERENTS
Nicotine Polacrilex* 2 mg & 4 mg Lozenges

NOTE:

  • All products marked * are under exclusivity for BOTH, the US & Europe market.
  • All products marked ^ are under exclusivity for the US market.
  • All products marked # are under validation & will be available shortly for commercial supply.

Patented products are available for R&D purposes only as permitted under 35 U.S.C. Section 271 (e) (I).